Skye Bioscience, Inc. (SKYE)

Skye Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	10.14	7.85	6.09	4.92	4.34	4.39
Research & Development	6.58	5.82	6.01	2.93	1.94	2.24
Other Operating Expenses	21.06	21.06	6.21	0	0	0
Operating Expenses	37.79	34.74	18.31	7.85	6.29	6.63
Operating Income	-37.79	-34.74	-18.31	-7.85	-6.29	-6.63
Interest Expense / Income	1.32	0.91	0.67	0.77	0.71	1
Other Expense / Income	-1.62	2	0.5	-0.1	-0.44	-8.69
Pretax Income	-37.49	-37.64	-19.47	-8.52	-6.56	1.05
Income Tax	0.01	0	0.01	0	0	0
Net Income	-37.5	-37.64	-19.48	-8.52	-6.56	1.05
Shares Outstanding (Basic)	28	7	2	2	1	1
Shares Outstanding (Diluted)	28	7	2	2	1	1
Shares Change	643.18%	215.43%	36.56%	75.70%	36.48%	39.95%
EPS (Basic)	-2.34	-5.37	-8.77	-5.00	-7.50	2.50
EPS (Diluted)	-2.34	-5.37	-8.77	-5.00	-7.50	-12.50
Free Cash Flow	-14.61	-13.96	-12.77	-6.57	-6.06	-6.03
Free Cash Flow Per Share	-0.52	-1.99	-5.75	-4.04	-6.57	-11.15
Effective Tax Rate	-	-	-	-	-	0.15%
EBITDA	-36.05	-36.61	-18.69	-7.72	-5.85	2.06
Depreciation & Amortization	0.12	0.12	0.11	0.03	0	0
EBIT	-36.17	-36.73	-18.81	-7.75	-5.85	2.05

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).